## Yu Guo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8876478/publications.pdf

Version: 2024-02-01

10 papers	48 citations	1937685 4 h-index	7 g-index
10	10	10	40 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells. European Journal of Medicinal Chemistry, 2022, 235, 114257.	5.5	4
2	Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy. Molecules, 2022, 27, 2543.	3.8	1
3	A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?. Medicinal Chemistry Research, 2021, 30, 1230-1239.	2.4	1
4	An updated patent review of Akt inhibitors (2016-present). Expert Opinion on Therapeutic Patents, 2021, 31, 837-849.	5.0	8
5	Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: From Catalytic Site Inhibitors to Allosteric Inhibitors. ChemistrySelect, 2021, 6, 5504-5523.	1.5	3
6	Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction. European Journal of Medicinal Chemistry, 2021, 223, 113637.	5.5	13
7	Epstein–Barr Virus-Positive Langerhans Cell Sarcoma: Is There a Link? A Case Report. Frontiers in Oncology, 2021, 11, 769310.	2.8	O
8	Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. OncoTargets and Therapy, 2020, Volume 13, 11221-11235.	2.0	11
9	Comprehensive Analysis of mRNA Expression Profiles in Head and Neck Cancer by Using Robust Rank Aggregation and Weighted Gene Coexpression Network Analysis. BioMed Research International, 2020, 2020, 1-21.	1.9	4
10	Dysregulated microRNAs in laryngeal cancer: a comprehensive meta-analysis using a robust rank aggregation approach. Future Oncology, 2020, 16, 2723-2734.	2.4	3